Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Dr. Reddy's Laboratories Ltd Common Stock (RDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 2.7× Edgewise Therapeutics Inc. Common Stock's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| EWTX | RDY | |
|---|---|---|
Market Cap | $3.94B | $10.78B |
Volume | 810,104 | 2,724,343 |
Sector | Health | Health |
52-Week High | $48.35 | $15.38 |
52-Week Low | $14.89 | $11.38 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.48B | $10.68B |
Dividend Yield | — | 0.65% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About Dr. Reddy's Laboratories Ltd Common Stock
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →
